Swati Jagdale
1*, Apoorva Chandekar
11 Department of Pharmaceutics, MAEER’s Maharashtra Institute of Pharmacy, MIT Campus, S. No. 124, Kothrud, Pune 411038, Savitribai Phule Pune University, India.
Abstract
Purpose: Inflammatory
bowel disease (IBD) is a chronic, relapsing and often life-long disorder. The
best way to tackle IBD is to develop a site targeted drug delivery. Methylprednisolone is a potent
anti-inflammatory steroid. The
relative potency of methylprednisolone to hydrocortisone is at least four is to
one. The aim of the present research was to develop a colon targeted drug
delivery for treatment of IBD.
Methods: Compression coated drug delivery system was designed
and optimised. Core tablet contained drug, croscarmellose sodium
(CCS-superdisintegrant), avicel (binder) and dicalcium phosphate (diluent).
Design of experiment with 32 factorial design was applied for
optimization of compression coated delivery. Chitosan and cellulose acetate
phthalate were chosen as independent variables. Swelling
index, hardness and % drug release were dependant variables.
Results: Core
tablet (C5 batch) containing 2.15% CCS showed disintegration in less than
10sec. FTIR, UV and DSC study had shown absence of any significant physical and
chemical interaction between drug and polymers. F8 was found to be optimised
formulation. F8 contained 35% chitosan and 17.5% cellulose acetate phthalate.
It showed drug release of 86.3% ± 6.1%, hardness 6.5 ± 1.5 and lag time 7 hrs.
Simulated media drug release was 97.51 ± 8.6% with 7.5 hrs lag time. The
results confirmed that the lag time was highly affected by the coating of the
polymers as well as the concentration of the superdisintegrant used in core
tablet.
Conclusion: In-vitro and in-vivo
results confirmed a potential colon targeted drug therapy for treatment of IBD.